

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: John B. Harley, Judith Ann James, and Kenneth M. Kaufman

Serial No.: Divisional of 09/718,693 Art Unit: Not Yet Assigned

Filed: August 22, 2003 Examiner: Not Yet Assigned

For: *ASSAYS AND THERAPIES FOR LATENT VIRAL INFECTION*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including fifteen (15) pages of Form PTO-1449. All of the documents cited below were cited by or submitted to the Patent Office in Application Serial No. 09/718,693, filed November 22, 2000, to which the present application claims priority. Pursuant to 37 C.F.R. §1.98(d), Applicants are not enclosing copies of these publications. Copies will be provided upon request, however.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

U.S.S.N.: Divisional of 09/718,693
Filed: August 22, 2003
INFORMATION DISCLOSURE STATEMENT

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
4,244,946	01-13-1981	Rivier, et al.	424/177
4,305,872	12-15-1981	Johnston, et al.	260/112.5R
4,316,891	02-23-1982	Guillemin, et al.	424/177
4,675,382	06-23-1987	Murphy	530/350
4,792,525	12-20-1988	Ruoslahti, et al.	435/240.243
5,637,454	06-10-1997	Harley	435/5
5,906,820	05-25-1999	Bacha	424/183.1

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
WO 98/30586	07-16-1998	Oklahoma Medical Research Foundation	PCT
WO 99/02550	01-21-1999	Queensland Institute for Medical Research	PCT

Publications

ADELSTEIN, et al., *Nucl. Med. Biol.* 14: 165-169 (1987).

ALFORD, Antiviral agents and viral diseases of man 2nd ed. Raven Press: New York, pp. 433-86 (1984).

ALSBAUGH, et al., *Arthr. Rheum.* 19: 711-719 (1976).

ALSBAUGH, et al., *J. Clin. Invest.* 67: 1134-1140 (1981).

ASHLEY, et al., "Detection of asymptomatic herpes simplex virus infections after vaccination," *J. Virol.* 61: 253-258 (1987).

BABCOCK, et al., *J. Exp. Med.* 190: 567-576 (1999).

BARNES, *Pharma Weekly* 1: 11 (1995).

BELL, et al., *J. Rheumatol.* 11: 277-281 (1984).

BRAY, et al., "Antibodies Against Epstein-Barr Nuclear Antigen (EBNA) in Multiple Sclerosis CSF, and Two Pentapeptide Sequence Identities Between EBNA and Myelin Basic Protein," *Arch. Neurol.* 42: 1798-1804 (1992).

*BRAY, et al., *Arch. Neurol.* 40: 406-408 (1983).

BROWNING, et al., *J. Immunol.* 143: 1859-1867 (1989).

CALDERWOOD, et al., "Nucleotide sequence of the Shiga-like toxin genes of *Escherichia coli*," *Proc. Natl. Acad. Sci. USA* 84: 4364-4368 (1987).

CATALANO, et al., "Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis," *Proc. Natl. Acad. Sci. USA* 76: 5825-5828 (1979).

CHEN, et al., *J. Biol. Chem.* 266: 18237-18243 (1991).

COLOMBATTI, et al., *J. Biol. Chem.* 261: 3030-3035 (1986).

DALLDORF, et al., "The Lymphomas of Brazilian Children," *J. Am. Med. Assn.* 208: 1365-8 (1969).

DEACON, et al., "Detection of Epstein-Barr Virus Antigens and DNA in Major and Minor Salivary Glands Using Immunocytochemistry and Polymerase Chain Reaction: Possible Relationship with Sjogren's Syndrome," *J. Pathol.* 163: 351-360 (1991).

DEACON, et al., "Frequency of EBV DNA Detection in Sjogren's Syndrome," *Am J. Med.* 92: 453-454 (1992).

DEBRUS, et al., "Varicella-zoster virus gene 63 encodes an immediate-early protein that is abundantly expressed during latency," *J. Virol.* 69: 3240-3245 (1995).

DEDRICK, et al., *Cancer Treat. Rep.* 62: 1-11 (1978).

DELEERS, et al., *FEBS Lett.* 160: 82-86 (1983).

DIENER, et al., "Specific Immunosuppression by Immunotoxins Containing Daunomycin," *Science* 231(4734): 148-150 (1986).

DIGARD, et al., "Functional analysis of the herpes simplex virus UL42 protein," *J. Virol.* 67: 1159-1168 (1993).

DITTMER, et al., "A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus," *J. Virol.* 72: 8309-8315 (1998).

DONAHUE, et al., *Arch. Int. Med.* 155: 1605-1609 (1995).

ELEK, et al., *Lancet* 1: 1-5 (1974).

U.S.S.N.: Divisional of 09/718,693
Filed: August 22, 2003
INFORMATION DISCLOSURE STATEMENT

ERTL, et al., "Physical and functional interaction of human cytomegalovirus DNA polymerase and its accessory protein (ICP36) expressed in insect cells," *J. Virol.* 66: 4126-33 (1992).

FERREL, et al., *J. Clin. Invest.* 67: 681-687 (1981).

FINERTY, et al., "Immunization of Cottontop Tamarins and Rabbits with a Candidate Vaccine Against the Epstein-Barr Virus Based on the Major Viral Envelope Glycoprotein gp340 and Alum," *Vaccine* 12: 1180-1184 (1994).

FINERTY, et al., "Protective Immunization Against Epstein-Barr Virus-Induced Disease in Cottontop Tamarins Using the Virus Envelope glycoprotein gp340 Produced from a Bovine Papillomavirus Expression Vector," *J. Gen. Virol.* 73: 449-453 (1992).

FOX, "Sjogren's Syndrome," *Current Opin. Rheum.* 7: 409-416 (1995).

FOX, et al., "Detection of Epstein-Barr Virus-Associated Antigens and DNA in Salivary Gland Biopsies from Patients with Sjogren's Syndrome," *J. Immunol.* 137: 3162-3168 (1986).

FOX, et al., "Potential Role of Epstein-Barr Virus in Sjogren's Syndrome and Rheumatoid Arthritis," *J. Rheumatol.* 19: 18-24 (1992).

GLASSY, et al., *J. Immunol. Methods* 81: 115 (1985).

GOODRICH, et al., *Ann. Intern. Med.* 118:173-178 (1993).

GRAY, et al., "Cloning, nucleotide sequence, and expression in *Escherichia coli* of the exotoxin A structural gene of *Pseudomonas aeruginosa*," *Proc. Natl. Acad. Sci. USA* 81: 2645-2649 (1984).

GREENWOOD, et al., *Biochem. J.* 89: 114-123 (1963).

GRIFFITHS, et al., *Cancer Res.* 51: 4594-4602 (1991).

GU, et al., "First EBV Vaccine Trial in Humans Using Recombinant Vaccinia Virus Expressing the Major Membrane Antigen," *Dev. Biol. Stand.* 84: 171-177 (1995).

GUTIERREZ, et al., "Switching Viral Latency to Viral Lysis: A Novel Therapeutic Approach for Epstein-Barr Virus-Associated Neoplasia," *Cancer Res.* 56: 969-972 (1996).

HAAHR, et al., "A Putative New Retrovirus Associated with Multiple Sclerosis and the Possible Involvement of Epstein-Barr Virus in This Disease," *Ann. N. Y. Acad. Sci.* 724: 148-156 (1996).

HALPERN, et al., *J. Nucl. Med.* 29: 1688-1696 (1988).

HARLEY & JAMES, "Epstein-Barr virus infection may be an environmental risk factor for systemic lupus erythematosus in children and teenagers," *Arthr. Rheum.* 42(8): 1782-1783 (1999).

HESLOP, et al., "Long-Term Restoration of Immunity Against Epstein-Barr Virus Infection by Adoptive Transfer of Gene-Modified Virus-Specific T Lymphocytes," *Nature Med.* 2: 551-555 (1996).

HISKEY, *Peptides* 3: 137 (1981).

HO, Cytomegalovirus, biology and infection: current topics in infectious disease Plenum Press: New York, pp. 105-118 (1982).

HOCH, et al., "Channels formed by botulinum, tetanus, and diphtheria toxins in planar lipid bilayers: relevance to translocation of proteins across membranes," *Proc. Natl. Acad. Sci. USA* 82: 1692-1696 (1985).

HWANG, et al., *Cell* 48: 129-136 (1987).

INOUE, et al., "Analysis of Antibody Titers to Epstein-Barr Virus Nuclear Antigens in Sera of Patients with Sjogren's Syndrome and with Rheumatoid Arthritis," *J. Infect. Dis.* 164: 22-28 (1991).

ISHII, et al., "Cycloheximide-Induced Apoptosis in Burkitt Lymphoma (BJA-B) Cells with and Without Epstein-Barr Virus Infection," *Immunol. Cell Biol.* 73: 463-468 (1995).

JAMES & HARLEY, "Linear Epitope Mapping of an Sm B/B' Polypeptide," *J. Immunol.* 148: 2074-2079 (1992).

JAMES, et al., "Immunoglobulin Epitope Spreading and Autoimmune Disease After Peptide Immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP Induce Spliceosome Autoimmunity," *J. Exp. Med.* 181: 453-461 (1995).

JAMES, et al., "An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus," *J. Clin. Invest.* 100: 3019-26 (1997).

JAMES, et al., *Arthr. Rheum.* 41: S308 (1998).

JI, *Meth. Enzymol.* 91: 580-609 (1983).

KAHAN, et al., *Arthr. Rheum.* 28: 961-70 (1985).

INFORMATION DISCLOSURE STATEMENT

KARAMERIS, et al., "Detection of the Epstein Barr Viral Genome by an *in situ* Hybridization Method in Salivary Gland Biopsies from Patients with Secondary Sjogren's Syndrome," *Clin. Exp. Rheum.* 10: 327-332 (1992).

KHANNA, et al., "Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: Implications for cytotoxic T-lymphocyte control of EBV-associated malignancies," *J Virology* 70(8): 5357-5362 (1996).

KIMURA, et al., *Clin. Exp. Immunol.* 103: 192-298 (1996).

KITAGAWA, et al., "Detection of Antibodies to the Epstein-Barr Virus Nuclear Antigens in the Sera from Patients with Systemic Lupus Erythematosus," *Immunol. Lett.* 17:249-252 (1988).

KOHLER & MILSTEIN, *Nature* 256: 495-497 (1975).

KOHLER & MILSTEIN, *Eur. J. Immunol.* 6: 511-519 (1976).

KOIDE, et al., "Spontaneous establishment of an Epstein-Barr virus-infected fibroblast line from the synovial tissue of a rheumatoid arthritis patient," *J. Virol.* 71: 2478-2481 (1997).

KONDO & YAMANISHI, 24th International Herpesvirus Workshop, July 17-23 (Mass. Inst. Tech.) Abst. 1.016 (1999).

KONDO, et al., "Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals," *Proc. Natl. Acad. Sci. USA* 93: 11137-11142 (1996).

KOYAMA, et al., *Chem. Abstr.* 120: 217-262 (1994).

KRAUSE & STRAUSS, *Infect. Dis. Clin. N.A.* 13: 61-81 (1999).

LARSEN, et al., "Epstein-Barr Nuclear Antigen and Viral Capsid Antigen Antibody Titers in Multiple Sclerosis," *Neurology* 35:435-438 (1985).

LAZAROVITS, et al., "Anti-B Cell Antibodies for the Treatment of Monoclonal Epstein-Barr Virus-Induced Lymphoproliferative Syndrome After Multivisceral Transplantation," *Clin. Invest. Med.* 17:621-625 (1994).

LENNETTE, et al., "Antibodies to LMP2A/2B in EBV-carrying malignancies," *Eur. J. Cancer* 31(11): 1875-1878 (1995).

LEVITSKAYA, "Inhibition of Antigen Processing by the Internal Repeat Region of the Epstein-Barr Virus Nuclear Antigen-1," *Nature* 375:685-688 (1995).

U.S.S.N.: Divisional of 09/718,693
Filed: August 22, 2003
INFORMATION DISCLOSURE STATEMENT

LONGNECKER & KIEFF, "A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1," *J. Virol.* 64: 2319-2326 (1990).

MASSEN, et al., *Eur. J. Biochem.* 134: 32 (1983).

MAHALINGAM, et al., "Expression of protein encoded by Varicella-Zoster virus open reading frame 63 in latently infected human ganglionic neurons," *Proc. Nat'l. Acad. Sci., USA* 93: 2122-2124 (1996).

MAITLAND, "Frequency of EBV-DNA Detection in Sjogren's Syndrome," *Am. J. Med.* 96:97 (1994).

MARIETTE, et al., "Detection of Epstein-Barr Virus DNA by *in Situ* Hybridization and Polymerase Chain Reaction in Patients with Sjogren's Syndrome," *Am. J. Med.* 90:286-294 (1991).

MARKMAN, *Semin. Oncol.* 18: 248-254 (1991).

MEANS, et al., Chemical modifications of proteins Holden-Day: San Francisco, pp. 105-110 (1971).

MEARES, et al., *Anal. Biochem.* 142: 68-78 (1984).

MEIGNER, et al., *J. Infect. Dis.* 162: 313-321 (1990).

MERRIFIELD, *J. Am. Chem. Soc.* 85: 2149 (1964).

MIYASHITA, et al., "Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell," *J. Virol.* 71: 4882-4891 (1997).

MOCARSKI, "Cytomegaloviruses and their replication" in Fields Virology, 3rd ed. (Fields, et al. eds.) Lippincott-Raven pp. 2447-2480 (1996).

MORGAN, "Epstein-Barr Virus Vaccines," *Vaccine* 10:563-571 (1992).

MORGAN, et al., "Validation of a First-Generation Epstein-Barr Virus Vaccine Preparation Suitable for Human Use," *J. Med. Virol.* 29:74-78 (1989).

MORSHED, et al., "Increased Expression of Epstein-Barr Virus in Primary Biliary Cirrhosis Patients," *Gastroenterol. Jpn.* 27(6):751-758 (1992).

MUJOO, et al., *Oncogene* 12:1617-1623 (1996).

MUSAINI, et al., *Ann. Rheum. Dis.* 46: 837-42 (1987).

U.S.S.N.: Divisional of 09/718,693
Filed: August 22, 2003
INFORMATION DISCLOSURE STATEMENT

MYERS, et al., *J. Immunol. Meth.* 121(1): 129-142 (1989).

NAKABAYASHI, et al., *Rheumatol. Int.* 5: 61-7 (1985).

NEWKIRK, et al., "Detection of Cytomegalovirus, Epstein-Barr Virus and Herpes Virus-6 in Patients with Rheumatoid Arthritis With or Without Sjogren's Syndrome," *Br. J. Rhuem.* 33:317-322 (1994).

NG, et al., *Lancet* 1(8166): 447-9 (1980).

OI, et al., "Chimeric antibodies," *BioTechniques* 4(3): 214 (1986).

PALLESEN, et al., "Expression of Epstein-Barr Virus Latent Gene Products in Tumor Cells of Hodgkin's Disease," *Lancet* 337(8737): 320-322 (1991).

PFLUGFELDER, et al., "Amplification of Epstein-Barr Virus Genomic Sequences in Blood Cells, Lacrimal Glands, and Tears from Primary Sjogren's Syndrome Patients," *Ophthalmology* 97:976-984 (1990).

PFLUGFELDER, et al., "Epstien-Barr Virus and the Lacrimal Gland Pathology of Sjogren's Syndrome," *Am. J. Pathol.* 143:49-64 (1993).

PLOTKIN, et al., *J. Infect. Dis.* 159: 860-565 (1989).

PLOTKIN, et al., *Infect. Immun.* 12: 521-527 (1975).

PLOTKIN, et al., *Rev. Infect. Dis.* 12: 827-838 (1990).

QUADRI, et al., *Nucl. Med. Biol.* 20: 559-570 (1993).

REUSSER, et al., *J. Infect. Dis.* 166: 473-479 (1992).

RICKINSON & KIEFF, "Epstein-Barr virus" in Fields Virology Lippincott-Raven, pp. 2397-2446 (1996).

RODWELL, et al., "Site-specific covalent modification of monoclonal antibodies: *in vitro* and *in vivo* evaluations," *Proc. Natl. Acad. Sci.* 83: 2632-2636 (1986).

ROWE, et al., *J. Gen. Virol.* 69: 1217-1228 (1988).

ROWLINSON, et al., *Cancer Res.* 47: 6528-6531 (1987).

SABBATINI, et al., "Autoantibodies from Patients with Systemic Lupus Erythematosus Bind a Shared Sequence of AmD and Epstein-Barr Virus-Encoded Nuclear Antigen EBNA I," *Eur. J. Immunol.* 23:1146-1152 (1993).

SADZOT-DELVAUX & BENTIER, 24th International Herpesvirus Workshop July 17-23 (Mass. Inst. Tech.) Abst. 9.009 (1999).

SADZOT-DELVAUX, et al., *J. Immunol.* 159: 2802 (1997).

SALACINSKI, et al., *Anal. Biochem.* 117: 136-146 (1981).

SCHMIDT, et al., " *Proc. Natl. Acad. Sci. USA* 88(21): 9478-9482 (1991).

SCOTET, et al., *J. Exp. Med.* 184: 1771-1780 (1996).

SCOTET, et al., "Frequent enrichment for CD8 T cells reactive against common herpes viruses in chronic inflammatory lesions: towards a reassessment of the physiopathological significance of T cell clonal expansions found in autoimmune inflammatory processes," *Eur J. Immunol.* 29: 973-985 (1999).

SCULLEY, et al., "Reactions of Sera from Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus and Infectious Mononucleosis to Epstein-Barr Virus-Induced Polypeptides," *J. Gen. Virol.* 67:2253-2258 (1986).

SINGH, et al., "Decreased Incidence of Viral Infections in Liver Transplant Recipients - Possible Effects of FK506?," *Digestive Dis. Sci.* 39:15-18 (1994).

SNOECK, et al., Multidisciplinary approach to understanding cytomegalovirus disease Excerpta Medica: Amsterdam, pp. 269-278 (1993).

SPAETE, *Transplant Proc.* 23: 90-96 (1991).

SPIRA, et al., *J. Immunol. Meth.* 74: 307 (1984).

STEPLEWSKI, et al., "Isolation and characterization of anti-monosialoganglioside monoclonal antibody 19-9 class-switch variants," *Proc. Natl. Acad. Sci., USA* 82: 8653-8657 (1985).

STRAUS, et al., *Ann. Int. Med.* 108: 221 (1988).

SUMAYA, et al., "Increased Prevalence and Titer of Epstein-Barr Virus Antibodies in Patients with Multiple Sclerosis," *Ann. Neurol.* 17:371-377 (1985).

SUN, et al., *Hybridoma* 5(Supp1): S17 (1986).

SUNDBERG, et al., *Nature* 250: 587-588 (1974).

TAKEI, et al., *Int. Immunol.* 9: 739-743 (1997).

U.S.S.N.: Divisional of 09/718,693

Filed: August 22, 2003

INFORMATION DISCLOSURE STATEMENT

TAN, *Rev. Inf. Dis.* 1: 997-1006 (1979).

TATEISHI, et al., "Spontaneous Production of Epstein-Barr Virus by B Lymphoblastoid Cell Lines Obtained from Patients with Sjogren's Syndrome," *Arthritis Rhuem.* 36:827-835 (1993).

THORLEY-LAWSON, et al., "Epstein-Barr virus and the B cell: that's all it takes," *Trends in Microbiology* 4(5): 204-208 (1996).

TODA, et al., "Sjogren's syndrome (SS) and Epstein-Barr virus (EBV) reactivation," In Lacrimal Gland, Tear Film, and Dry Eye Syndrome. (D.A. Sullivan, ed.) pp. 647-650 (Plenum Press, New York 1994).

TSAI, et al., "Detection of Epstein-Barr Virus and Cytomegalovirus Genome in White Blood Cells from Patients with Juvenile Rheumatoid Arthritis and Childhood Systemic Lupus Erythematosus," *Int. Arch. Allergy Immunol.* 106:235-240 (1995).

VENABLES, et al., "Persistence of Epstein-Barr Virus in Salivary Gland Biopsies from Healthy Individuals and Patients with Sjogren's Syndrome," *Clin. Exp. Immunol.*, 75:359-364 (1989).

VENABLES, et al., "The Response to Epstein-Barr Virus Infection in Sjogren's Syndrome," *J. Autoimmunity* 2:439-448 (1989).

VENABLES, et al., *Arthr. Rheum.* 24: 1459-1468 (1981).

VRISENDORP, et al., "Radioimmunoglobulin therapy" in High Dose Cancer Therapy (Armitage, et al. eds) Williams & Wilkins: Baltimore, pp. 84-123 (1992).

WAGSTAFF, et al., "Aciclovir - A Reappraisal of its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Efficacy," *Drugs* 47:153-205 (1994).

WANG, et al., *Radiat. Res.* 141: 292-302 (1995).

WARNER & CARP, "Multiple Sclerosis Etiology - an Epstein-Barr Virus Hypothesis," *Med. Hypotheses* 25:93-97 (1988).

WATSON, et al., "Certain Properties Make Substances Antigenic," in Molecular Biology of the Gene, Fourth Edition, page 836, paragraph 3, (The Benjamin/Cummings Publishing Company, Menlo Park, 1987).

WHITLEY, "Herpes Simplex viruses" in Field's Virology Lippincott-Raven, pp. 2297-2330 (1996).

U.S.S.N.: Divisional of 09/718,693
Filed: August 22, 2003
INFORMATION DISCLOSURE STATEMENT

WHITTINGHAM, et al., "Epstein-Barr Virus as an Etiological Agent in Primary Sjogren's Syndrome," *Med. Hypothesis*, 22:373-386 (1987).

WILBUR, *Antibiot. Immunoconj. Radiopharm.* 4: 85-97 (1991).

WILSON, et al., "Association of Lymphomatoid Granulomatosis With Epstein-Barr Viral Infection of B Lymphocytes and Response to Interferon- α 2b," *Blood*, 87:4531-4537 (1996).

XIE & SNYDER, "Two Short Autoepitopes on the Nuclear Dot Antigen Are Similar to Epitopes Encoded by the Epstein-Barr Virus," *Proc. Natl. Acad. Sci.* 92:1639-1643 (1995).

YOKOCHI, et al., "Hight Titer of Antibody to the Epstein-Barr Virus Membrane Antigen in Sera from Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus," *J. Rheumatol.* 16:1029-1032 (1989).

YUAN, et al., "Preparation and application of anti-EBNA 1 monoclonal antibodies," *Chinese J. Microbiol. Immunol.* 9(3): 198-202 (1989).


ZARLING, et al., "Herpes simplex virus (HSV)-specific proliferative and cytotoxic T-cell responses in humans immunized with an HSV type 2 glycoprotein subunit vaccine," *J. Virol.* 62: 4481-4485 (1988).

U.S.S.N.: Divisional of 09/718,693
Filed: August 22, 2003
INFORMATION DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Dated: August 22, 2003

HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588
www.hklaw.com
ATL1 #590606 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(use as many sheets as necessary)			
Application Number	Divisional f 09/718,693		
Filing Date	August 22, 2003		
First Named Inventor	John B. Harley		
Group Art Unit			
Examiner Name			
Sheet	1	of	15
			Attorney Docket Number
			OMRF 177 DIV

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examine
Signature _____ Date Considered _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	Divisional of 09/718,693
Sheet	2	of	15
			Attorney Docket Number
			OMRF 177 DIV

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		ADELSTEIN, et al., <i>Nucl. Med. Biol.</i> 14: 165-169 (1987).
		ALFORD, <i>Antiviral agents and viral diseases of man</i> 2 nd ed. Raven Press: New York, pp. 433-86 (1984).
		ALSBAUGH, et al., <i>Arthr. Rheum.</i> 19: 711-719 (1976).
		ALSBAUGH, et al., <i>J. Clin. Invest.</i> 67: 1134-1140 (1981).
		ASHLEY, et al., "Detection of asymptomatic herpes simplex virus infections after vaccination," <i>J. Virol.</i> 61: 253-258 (1987).
		BABCOCK, et al., <i>J. Exp. Med.</i> 190: 567-576 (1999).
		BARNES, <i>Pharma Weekly</i> 1: 11 (1995).
		BELL, et al., <i>J. Rheumatol.</i> 11: 277-281 (1984).
		BRAY, et al., "Antibodies Against Epstein-Barr Nuclear Antigen (EBNA) in Multiple Sclerosis CSF, and Two Pentapeptide Sequence Identities Between EBNA and Myelin Basic Protein," <i>Arch. Neurol.</i> 42: 1798-1804 (1992).
		BRAY, et al., <i>Arch. Neurol.</i> 40: 406-408 (1983).

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Compl t If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Divisional of 09/718,693
Sheet	3	of	15
		Attorney Docket Number	OMRF 177 DIV

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		BROWNING, et al., <i>J. Immunol.</i> 143: 1859-1867 (1989).
		CALDERWOOD, et al., "Nucleotide sequence of the Shiga-like toxin genes of <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 84: 4364-4368 (1987).
		CATALANO, et al., "Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis," <i>Proc. Natl. Acad. Sci USA</i> 76: 5825-5828 (1979).
		CHEN, et al., <i>J. Biol. Chem.</i> 266: 18237-18243 (1991).
		COLOMBATTI, et al., <i>J. Biol. Chem.</i> 261: 3030-3035 (1986).
		DALLDORF, et al., "The Lymphomas of Brazilian Children," <i>J. Am. Med. Assn.</i> 208: 1365-8 (1969).
		DEACON, et al., "Detection of Epstein-Barr Virus Antigens and DNA in Major and Minor Salivary Glands Using Immunocytochemistry and Polymerase Chain Reaction: Possible Relationship with Sjogren's Syndrome," <i>J. Pathol.</i> 163: 351-360 (1991).
		DEACON, et al., "Frequency of EBV DNA Detection in Sjogren's Syndrome," <i>Am J. Med.</i> 92: 453-454 (1992).
		DEBRUS, et al., "Varicella-zoster virus gene 63 encodes an immediate-early protein that is abundantly expressed during latency," <i>J. Virol.</i> 69: 3240-3245 (1995).
		DEDRICK, et al., <i>Cancer Treat. Rep.</i> 62: 1-11 (1978).

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Divisional of 09/718,693
Sheet	4	of	15
		Attorney Docket Number	OMRF 177 DIV

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		DELEERS, et al., <i>FEBS Lett.</i> 160: 82-86 (1983).	
		DIENER, et al., "Specific Immunosuppression by Immunotoxins Containing Daunomycin," <i>Science</i> 231(4734): 148-150 (1986).	
		DIGARD, et al., "Functional analysis of the herpes simplex virus UL42 protein," <i>J. Virol.</i> 67: 1159-1168 (1993).	
		DITTMER, et al., "A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus," <i>J. Virol.</i> 72: 8309-8315 (1998).	
		DONAHUE, et al., <i>Arch. Int. Med.</i> 155: 1605-1609 (1995).	
		ELEK, et al., <i>Lancet</i> 1: 1-5 (1974).	
		ERTL, et al., "Physical and functional interaction of human cytomegalovirus DNA polymerase and its accessory protein (ICP36) expressed in insect cells," <i>J. Virol.</i> 66: 4126-33 (1992).	
		FERREL, et al., <i>J. Clin. Invest.</i> 67: 681-687 (1981).	
		FINERTY, et al., "Immunization of Cottontop Tamarins and Rabbits with a Candidate Vaccine Against the Epstein-Barr Virus Based on the Major Viral Envelope Glycoprotein gp340 and Alum," <i>Vaccine</i> 12: 1180-1184 (1994).	
		FINERTY, et al., "Protective Immunization Against Epstein-Barr Virus-Induced Disease in Cottontop Tamarins Using the Virus Envelope glycoprotein gp340 Produced from a Bovine Papillomavirus Expression Vector," <i>J. Gen. Virol.</i> 73: 449-453 (1992).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Divisional of 09/718,693
Filing Date	August 22, 2003		
First Named Inventor	John B. Harley		
Group Art Unit			
Examiner Name			
Sheet 5 of 15	Attorney Docket Number	OMRF 177 DIV	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		FOX, "Sjogren's Syndrome," <i>Current Opin. Rheum.</i> 7: 409-416 (1995).	
		FOX, et al., "Detection of Epstein-Barr Virus-Associated Antigens and DNA in Salivary Gland Biopsies from Patients with Sjogren's Syndrome," <i>J. Immunol.</i> 137: 3162-3168 (1986).	
		FOX, et al., "Potential Role of Epstein-Barr Virus in Sjogren's Syndrome and Rheumatoid Arthritis," <i>J. Rheumatol.</i> 19: 18-24 (1992).	
		GLASSY, et al., <i>J. Immunol. Methods</i> 81: 115 (1985).	
		GOODRICH, et al., <i>Ann. Intern. Med.</i> 118:173-178 (1993).	
		GRAY, et al., "Cloning, nucleotide sequence, and expression in <i>Escherichia coli</i> of the exotoxin A structural gene of <i>Pseudomonas aeruginosa</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 81: 2645-2649 (1984).	
		GREENWOOD, et al., <i>Biochem. J.</i> 89: 114-123 (1963).	
		GRIFFITHS, et al., <i>Cancer Res.</i> 51: 4594-4602 (1991).	
		GU, et al., "First EBV Vaccine Trial in Humans Using Recombinant Vaccinia Virus Expressing the Major Membrane Antigen," <i>Dev. Biol. Stand.</i> 84: 171-177 (1995).	
		GUTIERREZ, et al., "Switching Viral Latency to Viral Lysis: A Novel Therapeutic Approach for Epstein-Barr Virus-Associated Neoplasia," <i>Cancer Res.</i> 56: 969-972 (1996).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	Divisional of 09/718,693
(use as many sheets as necessary)		Filing Date	August 22, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet	6	of	15
		Attorney Docket Number	OMRF 177 DIV

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		HAAHR, et al., "A Putative New Retrovirus Associated with Multiple Sclerosis and the Possible Involvement of Epstein-Barr Virus in This Disease," <i>Ann. N. Y. Acad. Sci.</i> 724: 148-156 (1996).	
		HALPERN, et al., <i>J. Nucl. Med.</i> 29: 1688-1696 (1988).	
		HARLEY & JAMES, "Epstein-Barr virus infection may be an environmental risk factor for systemic lupus erythematosus in children and teenagers," <i>Arthr. Rheum.</i> 42(8): 1782-1783 (1999).	
		HESLOP, et al., "Long-Term Restoration of Immunity Against Epstein-Barr Virus Infection by Adoptive Transfer of Gene-Modified Virus-Specific T Lymphocytes," <i>Nature Med.</i> 2: 551-555 (1996).	
		HISKEY, <i>Peptides</i> 3: 137 (1981).	
		HO, <i>Cytomegalovirus, biology and infection: current topics in infectious disease</i> Plenum Press: New York, pp. 105-118 (1982).	
		HOCH, et al., "Channels formed by botulinum, tetanus, and diphtheria toxins in planar lipid bilayers: relevance to translocation of proteins across membranes," <i>Proc. Natl. Acad. Sci. USA</i> 82: 1692-1696 (1985).	
		HWANG, et al., <i>Cell</i> 48: 129-136 (1987).	
		INOUE, et al., "Analysis of Antibody Titers to Epstein-Barr Virus Nuclear Antigens in Sera of Patients with Sjogren's Syndrome and with Rheumatoid Arthritis," <i>J. Infect. Dis.</i> 164: 22-28 (1991).	
		ISHII, et al., "Cycloheximide-Induced Apoptosis in Burkitt Lymphoma (BJA-B) Cells with and Without Epstein-Barr Virus Infection," <i>Immunol. Cell Biol.</i> 73: 463-468 (1995).	

Examiner's Signature _____ Date Considered _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Divisional of 09/718,693
Sheet	7	of	15
		Filing Date	August 22, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	OMRF 177 DIV

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ³
		JAMES & HARLEY, "Linear Epitope Mapping of an Sm B/B' Polypeptide," <i>J. Immunol.</i> 148: 2074-2079 (1992).	
		JAMES, et al., "Immunoglobulin Epitope Spreading and Autoimmune Disease After Peptide Immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP Induce Spliceosome Autoimmunity," <i>J. Exp. Med.</i> 181: 453-461 (1995).	
		JAMES, et al., "An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus," <i>J. Clin. Invest.</i> 100: 3019-26 (1997).	
		JAMES, et al., <i>Arthr. Rheum.</i> 41: S308 (1998).	
		JI, <i>Meth. Enzymol.</i> 91: 580-609 (1983).	
		KAHAN, et al., <i>Arthr. Rheum.</i> 28: 961-70 (1985).	
		KARAMERIS, et al., "Detection of the Epstein Barr Viral Genome by an <i>in situ</i> Hybridization Method in Salivary Gland Biopsies from Patients with Secondary Sjogren's Syndrome," <i>Clin. Exp. Rheum.</i> 10: 327-332 (1992).	
		KHANNA, et al., "Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: Implications for cytotoxic T-lymphocyte control of EBV-associated malignancies," <i>J. Virology</i> 70(8): 5357-5362 (1996).	
		KIMURA, et al., <i>Clin. Exp. Immunol.</i> 103: 192-298 (1996).	
		KITAGAWA, et al., "Detection of Antibodies to the Epstein-Barr Virus Nuclear Antigens in the Sera from Patients with Systemic Lupus Erythematosus," <i>Immunol. Lett.</i> 17:249-252 (1988).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Completeness If Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	8	of	15	Attorney Docket Number	OMRF 177 DIV
-------	---	----	----	------------------------	--------------

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		KOHLER & MILSTEIN, <i>Nature</i> 256: 495-497 (1975).	
		KOHLER & MILSTEIN, <i>Eur. J. Immunol.</i> 6: 511-519 (1976).	
		KOIDE, et al., "Spontaneous establishment of an Epstein-Barr virus-infected fibroblast line from the synovial tissue of a rheumatoid arthritis patient," <i>J. Virol.</i> 71: 2478-2481 (1997).	
		KONDO & YAMANISHI, 24 th International Herpesvirus Workshop, July 17-23 (Mass. Inst. Tech.) Abst. 1.016 (1999).	
		KONDO, et al., "Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals," <i>Proc. Natl. Acad. Sci. USA</i> 93: 11137-1142 (1996).	
		KOYAMA, et al., <i>Chem. Abstr.</i> 120: 217-262 (1994).	
		KRAUSE & STRAUSS, <i>Infect. Dis. Clin. N.A.</i> 13: 61-81 (1999).	
		LARSEN, et al., "Epstein-Barr Nuclear Antigen and Viral Capsid Antigen Antibody Titers in Multiple Sclerosis," <i>Neurology</i> 35:435-438 (1985).	
		LAZAROVITS, et al., "Anti-B Cell Antibodies for the Treatment of Monoclonal Epstein-Barr Virus-Induced Lymphoproliferative Syndrome After Multivisceral Transplantation," <i>Clin. Invest. Med.</i> 17:621-625 (1994).	
		LENNETTE, et al., "Antibodies to LMP2A/2B in EBV-carrying malignancies," <i>Eur. J. Cancer</i> 31(11): 1875-1878 (1995).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Completeness If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Divisional 109/718,693
Sheet	9	of	15
		Attorney Docket Number	OMRF 177 DIV

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		LEVITSKAYA, "Inhibition of Antigen Processing by the Internal Repeat Region of the Epstein-Barr Virus Nuclear Antigen-1," <i>Nature</i> 375:685-688 (1995).	
		LONGNECKER & KIEFF, "A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1," <i>J. Virol.</i> 64: 2319-2326 (1990).	
		MASSEN, et al., <i>Eur. J. Biochem.</i> 134: 32 (1983).	
		MAHALINGAM, et al., "Expression of protein encoded by Varicella-Zoster virus open reading frame 63 in latently infected human ganglionic neurons," <i>Proc. Nat'l. Acad. Sci., USA</i> 93: 2122-2124 (1996).	
		MAITLAND, "Frequency of EBV-DNA Detection in Sjogren's Syndrome," <i>Am. J. Med.</i> 96:97 (1994).	
		MARIETTE, et al., "Detection of Epstein-Barr Virus DNA by <i>in Situ</i> Hybridization and Polymerase Chain Reaction in Patients with Sjogren's Syndrome," <i>Am. J. Med.</i> 90:286-294 (1991).	
		MARKMAN, <i>Semin. Oncol.</i> 18: 248-254 (1991).	
		MEANS, et al., <u>Chemical modifications of proteins Holden-Day</u> : San Francisco, pp. 105-110 (1971).	
		MEARES, et al., <i>Anal. Biochem.</i> 142: 68-78 (1984).	
		MEIGNER, et al., <i>J. Infect. Dis.</i> 162: 313-321 (1990).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Divisional of 09/718,693
Sheet	10	of	15
		Attorney Docket Number	OMRF 177 DIV

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		MERRIFIELD, J. Am. Chem. Soc. 85: 2149 (1964).
		MIYASHITA, et al., "Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell," J. Virol. 71: 4882-4891 (1997).
		MOCARSKI, "Cytomegaloviruses and their replication" in <i>Fields Virology</i> , 3 rd ed. (Fields, et al. eds.) Lippincott-Raven pp. 2447-2480 (1996).
		MORGAN, "Epstein-Barr Virus Vaccines," Vaccine 10:563-571 (1992).
		MORGAN, et al., "Validation of a First-Generation Epstein-Barr Virus Vaccine Preparation Suitable for Human Use," J. Med. Virol. 29:74-78 (1989).
		MORSHED, et al., "Increased Expression of Epstein-Barr Virus in Primary Biliary Cirrhosis Patients," Gastroenterol. Jpn. 27(6):751-758 (1992).
		MUJOO, et al., Oncogene 12:1617-1623 (1996).
		MUSAINI, et al., Ann. Rheum. Dis. 46: 837-42 (1987).
		MYERS, et al., J. Immunol. Meth. 121(1): 129-142 (1989).
		NAKABAYASHI, et al., Rheumatol. Int. 5: 61-7 (1985).

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Divisional of 09/718,693
Filing Date	August 22, 2003		
First Named Inventor	John B. Harley		
Group Art Unit			
Examiner Name			
Sheet 11 of 15	Attorney Docket Number	OMRF 177 DIV	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		NEWKIRK, et al., "Detection of Cytomegalovirus, Epstein-Barr Virus and Herpes Virus-6 in Patients with Rheumatoid Arthritis With or Without Sjogren's Syndrome," <i>Br. J. Rheum.</i> 33:317-322 (1994).
		NG, et al., <i>Lancet</i> 1(8166): 447-9 (1980).
		OI, et al., "Chimeric antibodies," <i>BioTechniques</i> 4(3): 214 (1986).
		PALLESEN, et al., "Expression of Epstein-Barr Virus Latent Gene Products in Tumor Cells of Hodgkin's Disease," <i>Lancet</i> 337(8737): 320-322 (1991).
		PFLUGFELDER, et al., "Amplification of Epstein-Barr Virus Genomic Sequences in Blood Cells, Lacrimal Glands, and Tears from Primary Sjogren's Syndrome Patients," <i>Ophthalmology</i> 97:976-984 (1990).
		PFLUGFELDER, et al., "Epstein-Barr Virus and the Lacrimal Gland Pathology of Sjogren's Syndrome," <i>Am. J. Pathol.</i> 143:49-64 (1993).
		PLOTKIN, et al., <i>J. Infect. Dis.</i> 159: 860-865 (1989).
		PLOTKIN, et al., <i>Infect. Immun.</i> 12: 521-527 (1975).
		PLOTKIN, et al., <i>Rev. Infect. Dis.</i> 12: 827-838 (1990).
		QUADRI, et al., <i>Nucl. Med. Biol.</i> 20: 559-570 (1993).

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Divisional 109/718,693
Sheet	12	of	15
			Attorney Docket Number
			OMRF 177 DIV

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		REUSSER, et al., <i>J. Infect. Dis.</i> 166: 473-479 (1992).
		RICKINSON & KIEFF, "Epstein-Barr virus" in <i>Fields Virology</i> , Lippincott-Raven, pp. 2397-2446 (1996).
		RODWELL, et al., "Site-specific covalent modification of monoclonal antibodies: <i>in vitro</i> and <i>in vivo</i> evaluations," <i>Proc. Natl. Acad. Sci.</i> 83: 2632-2636 (1986).
		ROWE, et al., <i>J. Gen. Virol.</i> 69: 1217-1228 (1988).
		ROWLINSON, et al., <i>Cancer Res.</i> 47: 6528-6531 (1987).
		SABBATINI, et al., "Autoantibodies from Patients with Systemic Lupus Erythematosus Bind a Shared Sequence of AnD and Epstein-Barr Virus-Encoded Nuclear Antigen EBNA I," <i>Eur. J. Immunol.</i> 23:1146-1152 (1993).
		SADZOT-DELVAUX & BENTIER, 24 th International Herpesvirus Workshop July 17-23 (Mass. Inst. Tech.) Abst. 9.009 (1999).
		SADZOT-DELVAUX, et al., <i>J. Immunol.</i> 159: 2802 (1997).
		SALACINSKI, et al., <i>Anal. Biochem.</i> 117: 136-146 (1981).
		SCHMIDT, et al., "Proc. Natl. Acad. Sci. USA 88(21): 9478-9482 (1991).

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Divisional of 09/718,693
Filing Date	August 22, 2003		
First Named Inventor	John B. Harley		
Group Art Unit			
Examiner Name			
Sheet 13 of 15	Attorney Docket Number	OMRF 177 DIV	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		SCOTET, et al., <i>J. Exp. Med.</i> 184: 1771-1780 (1996).	
		SCOTET, et al., "Frequent enrichment for CD8 T cells reactive against common herpes viruses in chronic inflammatory lesions: towards a reassessment of the physiopathological significance of T cell clonal expansions found in autoimmune inflammatory processes," <i>Eur J. Immunol.</i> 29: 973-985 (1999).	
		SCULLEY, et al., "Reactions of Sera from Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus and Infectious Mononucleosis to Epstein-Barr Virus-Induced Polypeptides," <i>J. Gen. Virol.</i> 67:2253-2258 (1986).	
		SINGH, et al., "Decreased Incidence of Viral Infections in Liver Transplant Recipients - Possible Effects of FK506?," <i>Digestive Dis. Sci.</i> 39:15-18 (1994).	
		SNOECK, et al., <i>Multidisciplinary approach to understanding cytomegalovirus disease Excerpta Medica: Amsterdam</i> , pp. 269-278 (1993).	
		SPAETE, <i>Transplant Proc.</i> 23: 90-96 (1991).	
		SPIRA, et al., <i>J. Immunol. Meth.</i> 74: 307 (1984).	
		STEPLEWSKI, et al., "Isolation and characterization of anti-monosialoganglioside monoclonal antibody 19-9 class-switch variants," <i>Proc. Natl. Acad. Sci., USA</i> 82: 8653-8657 (1985).	
		STRAUS, et al., <i>Ann. Int. Med.</i> 108: 221 (1988).	
		SUMAYA, et al., "Increased Prevalence and Titer of Epstein-Barr Virus Antibodies in Patients with Multiple Sclerosis," <i>Ann. Neurol.</i> 17:371-377 (1985).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Divisional 109/718,693
Filing Date	August 22, 2003		
First Named Inventor	John B. Harley		
Group Art Unit			
Examiner Name			
Sheet	14	of	15
		Attorney Docket Number	OMRF 177 DIV

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		SUN, et al., <i>Hybridoma</i> 5(Supp1): S17 (1986).	
		SUNDBERG, et al., <i>Nature</i> 250: 587-588 (1974).	
		TAKEI, et al., <i>Int. Immunol.</i> 9: 739-743 (1997).	
		TAN, <i>Rev. Inf. Dis.</i> 1: 997-1006 (1979).	
		TATEISHI, et al., "Spontaneous Production of Epstein-Barr Virus by B Lymphoblastoid Cell Lines Obtained from Patients with Sjogren's Syndrome," <i>Arthritis Rheum.</i> 36:827-835 (1993).	
		THORLEY-LAWSON, et al., "Epstein-Barr virus and the B cell: that's all it takes," <i>Trends in Microbiology</i> 4(5): 204-208 (1996).	
		TODA, et al., "Sjogren's syndrome (SS) and Epstein-Barr virus (EBV) reactivation," In <i>Lacrimal Gland, Tear Film, and Dry Eye Syndrome</i> , (D.A. Sullivan, ed.) pp. 647-650 (Plenum Press, New York 1994).	
		TSALI, et al., "Detection of Epstein-Barr Virus and Cytomegalovirus Genome in White Blood Cells from Patients with Juvenile Rheumatoid Arthritis and Childhood Systemic Lupus Erythematosus," <i>Int. Arch. Allergy Immunol.</i> 106:235-240 (1995).	
		VENABLES, et al., "Persistence of Epstein-Barr Virus in Salivary Gland Biopsies from Healthy Individuals and Patients with Sjogren's Syndrome," <i>Clin. Exp. Immunol.</i> 75:359-364 (1989).	
		VENABLES, et al., "The Response to Epstein-Barr Virus Infection in Sjogren's Syndrome," <i>J. Autoimmunity</i> 2:439-448 (1989).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	15	of	15	Attorney Docket Number	OMRF 177 DIV
-------	----	----	----	------------------------	--------------

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		VENABLES, et al., <i>Arthr. Rheum.</i> 24: 1459-1468 (1981).	
		VRISENDORP, et al., "Radioimmunoglobulin therapy" in <i>High Dose Cancer Therapy</i> (Armitage, et al. eds) Williams & Wilkins: Baltimore, pp. 84-123 (1992).	
		WAGSTAFF, et al., "Aciclovir - A Reappraisal of its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Efficacy," <i>Drugs</i> 47:153-205 (1994).	
		WANG, et al., <i>Radiat. Res.</i> 141: 292-302 (1995).	
		WARNER & CARP, "Multiple Sclerosis Etiology - an Epstein-Barr Virus Hypothesis," <i>Med. Hypotheses</i> 25:93-97 (1988).	
		WATSON, et al., "Certain Properties Make Substances Antigenic," in <i>Molecular Biology of the Gene</i> , Fourth Edition, page 836, paragraph 3, (The Benjamin/Cummings Publishing Company, Menlo Park, 1987).	
		WHITLEY, "Herpes Simplex viruses" in <i>Field's Virology</i> Lippincott-Raven, pp. 2297-2330 (1996).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+